Community/Retail

The investigators noted that the levels of islatravir in peripheral blood mononuclear cells remained above the efficacy pharmacokinetics threshold for PrEP for both doses studied (60 mg and 120 mg) for 8 weeks following the last study dose.

Vviloxazine (Qelbree) is a norepinephrine reuptake inhibitor that provides a new treatment option for patients aged 6 to 17 years with ADHD.

Reducing blood pressure is the major determinant of reduction in cardiovascular risk in both young and older patients with hypertension.

Penny pinchers, early arrivals, and more are featured in this month's Pet Peeves.

The FDA has approved the monoclonal antibody mepolizumab as a treatment for patients with chronic rhinosinusitis with nasal polyps.

This month's products include a smart pen cap for insulin dosing, a treatment for benign prostatic hyperplasia, and more.

Lipophilic statins for dyslipidemia penetrate muscle more easily than hydrophilic statins and are associated with a higher incidence of adverse effects.

The availability of insulin biosimilars can bring high-quality, lower cost treatment options for pharmacists, physicians, payers, and patients alike.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discusses what led to his interest in the position.

Companies and practitioners should take important steps to protect patients from these mistakes.

Women are significantly less likely than men to undergo coronary artery bypass grafting because of gender disparities in the understanding and treatment of coronary artery disease, research shows.

Insulin glargine-yfgn is the first interchangeable biosimilar product for the treatment of diabetes approved in the United States, which can provide patients with alternative, equally effective options for treating diabetes that could be more cost effective.

Blood pressure has to be monitored closely in patients diagnosed with stage 1 or 2 hypertension.

FDA approvals of vaccines usually take 10 to 15 years, but the pandemic necessitates emergency action.

Based on their findings, investigators said modifiable risk factors are strongly associated with C-reactive protein levels in patients with coronary artery disease.

A pooled analysis of a 48-week open-label extension of a pair of phase 3 studies found that 99% of patients with HIV who initiated treatment using bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets maintained an undetectable viral load through 4 years of follow-up.

Individuals with attention-deficit hyperactivity disorder and other diagnoses who are taking stimulant medications are also more likely to switch to non-stimulant medications.

These services include vaccinations, routine screenings, and physical exams.

Older drugs such as lovastatin (Mevacor, Altoprev), simvastatin (Zocor), and atorvastatin (Lipitor) have the most drug interactions.

Investigators hypothesize that concurrent symptoms of anxiety and depression may be linked to concerns about adverse events.

Officials with the CDC updated their COVID-19 guidelines today, urging that vaccinated individuals in areas of substantial and high transmission wear masks in public indoor spaces, including schools, in order to prevent the spread of the Delta variant.

Many pharmacists must find a way to vaccinate hundreds of patients in an organized way, while still having to run an understaffed pharmacy.

John M. O’Brien, PharmD, MPH, newly appointed President and CEO of the National Pharmaceutical Council, discussed his history prior to joining NPC.

The clinical trial expansion is part of efforts to detect potential adverse effects in children, such as heart inflammation problems.

Theresa McArdle, MBA, senior brand marketing manager at Pharmavite, to discuss new survey data that showed a decline in self-care among pharmacists coming out of the COVID-19 pandemic.

Ken Perez, MBA, vice president of healthcare policy and government affairs at Omnicell, discussed the pandemic's impact on the legislative push to grant pharmacists provider status for Medicare Part B.